Clinical outcomes in patients with early non-small-cell lung cancer treated surgically in Bogota (Colombia)

被引:0
|
作者
Alvarado-Sarzosa, Fernando [1 ]
Martinez-Jaramillo, Stella Isabel [2 ,3 ]
Hellal, Luis Gerardo Garcia-Herreros- [4 ]
Beltran-Jimenez, Rafael Jose [5 ]
Zuluaga-Restrepo, Juan David [6 ]
Parra-Medina, Rafael [7 ]
Escobar-avila, Laura Lucia [8 ]
Toledo-Arenas, Jose Daniel [9 ]
Carvajal-Fierro, Carlos Andres [5 ]
机构
[1] Univ Bosque, Programa Posgrad Cirugia Torax, Inst Nacl Cancerol, Convenio Docencia Serv, Bogota, DC, Colombia
[2] Cirugia Torax, Clin Reina Sofia, Bogota, DC, Colombia
[3] Univ Bosque, Programa Especializac Cirugia Torax, Bogota, DC, Colombia
[4] Fdn Santa Fe Bogota, Cirugia Torax, Bogota, DC, Colombia
[5] Inst Nacl Cancerol, Unidad Func Cirugia Torax, Bogota, DC, Colombia
[6] Clin CES, Cirugia Torax, Medellin, Colombia
[7] Inst Nacl Cancerol, Grp Patol Oncol, Bogota, DC, Colombia
[8] Lab Patol, Clin Reina Sofia, Bogota, DC, Colombia
[9] Univ Bosque, Psiquiatria & Epidemiol, , D C, Bogota, DC, Colombia
来源
REVISTA COLOMBIANA DE CANCEROLOGIA | 2023年 / 27卷 / 02期
关键词
Carcinoma; non-small-cell lung; adenocarcinoma of lung; neoplasm staging; recurrence; VISCERAL PLEURAL INVASION; INTERNATIONAL ASSOCIATION; GRADING SYSTEM; AIR SPACES; CLASSIFICATION; ADENOCARCINOMA; RECURRENCE; EPIDEMIOLOGY; REVISION; PROPOSAL;
D O I
10.35509/01239015.904
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: In Colombia, information is limited on the survival of patients with lung cancer treated in the early stages. Thus, this study aimed to analyze the clinical outcomes and factors associated with the prognosis of patients with non-small-cell lung cancer (NSCLC) treated surgically in three institutions in Bogota.Methods: Analytical, observational, retrospective, and multicenter study.Results: The study included 101 patients with a median age of 69 years (IQR 63-75); 56 were women (55.4%). Of the patients, 8 (7.9%) had pathological stage 0, 83 (82.2%) were in stage I and 10 (9.9%) in stage II. The 3-year disease-free survival (DFS) of patients with stages 0, I, and II was 100%, 97%, and 58%, respectively. The overall survival (OS) of all included patients at 3 years was 94%. The OS of patients with and without relapse was 78% and 96%. A statistically significant association was found between relapse and stage II (P<0.001), relapse and T3 (P=0.048), relapse and N1 (P<0.001), and relapse and visceral pleura invasion (P=0.002). The only association found with death was relapse (P=0.002).Conclusions: The pathological stage and some special TNM characteristics, such as T3 tumor, the presence of N1 disease, and visceral pleura invasion, were determining factors in DFS. In contrast, the only factor associated with worse OS was relapse.
引用
收藏
页码:240 / 250
页数:11
相关论文
共 50 条
  • [41] Erlotinib in previously treated non-small-cell lung cancer
    Shepherd, FA
    Pereira, JR
    Ciuleanu, T
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Campos, D
    Maoleekoonpiroj, S
    Smylie, M
    Martins, R
    van Kooten, M
    Dediu, M
    Findlay, B
    Tu, DS
    Johnston, D
    Bezjak, A
    Clark, G
    Santabárbara, P
    Seymour, L
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02): : 123 - 132
  • [42] Imaging surveillance and survival for surgically resected non-small-cell lung cancer
    Backhus, Leah M.
    Farjah, Farhood
    Liang, Chao-Kang Jason
    He, Hao
    Varghese, Thomas K., Jr.
    Au, David H.
    Flum, David R.
    Zeliadt, Steven B.
    JOURNAL OF SURGICAL RESEARCH, 2016, 200 (01) : 171 - 176
  • [43] PEMETREXED IN PREVIOUSLY TREATED NON-SMALL-CELL LUNG CANCER
    Cho, E.
    Hong, J.
    Kim, Y. S.
    Sim, S. J.
    Park, S. H.
    Park, J.
    Lee, J. H.
    Shin, D. B.
    ANNALS OF ONCOLOGY, 2008, 19 : 120 - 120
  • [44] Docetaxel for previously treated non-small-cell lung cancer
    Fossella, FV
    ONCOLOGY-NEW YORK, 2002, 16 (06): : 45 - 51
  • [45] Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
    Yuki Katayama
    Tadaaki Yamada
    Yusuke Chihara
    Satomi Tanaka
    Keiko Tanimura
    Naoko Okura
    Kazuki Hirose
    Sayaka Uda
    Shinsuke Shiotsu
    Soichi Hirai
    Osamu Hiranuma
    Taishi Harada
    Takayuki Shimamoto
    Masahiro Iwasaku
    Yoshiko Kaneko
    Junji Uchino
    Takayuki Takeda
    Koichi Takayama
    Scientific Reports, 10
  • [46] EARLY INTERDISCIPLINARY PALLIATIVE CARE FOR PATIENTS WITH NON-SMALL-CELL LUNG CANCER
    Aljohani, Abdulaziz
    RESPIROLOGY, 2015, 20 : 87 - 87
  • [47] Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy
    Sun, Lova
    Davis, Christiana W.
    Hwang, Wei-Ting
    Jeffries, Seth
    Sulyok, Lydia Frenzel
    Marmarelis, Melina E.
    Singh, Aditi P.
    Berman, Abigail T.
    Feigenberg, Steven J.
    Levin, William
    Ciunci, Christine A.
    Bauml, Joshua M.
    Cohen, Roger B.
    Langer, Corey J.
    Aggarwal, Charu
    CLINICAL LUNG CANCER, 2021, 22 (01) : 58 - +
  • [48] Surgical treatment outcomes on early-stages of non-small-cell lung cancer
    Leila, Fekih
    Mejri, Islam
    Ayari, Aymen
    Smadhi, Hanene
    Kammoun, Hela
    Hassene, Hela
    Greb, Dorra
    Abdelghaffar, Hajer
    Akrout, Ines
    Megdiche, Mohamed Lamine
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [49] Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
    Katayama, Yuki
    Yamada, Tadaaki
    Chihara, Yusuke
    Tanaka, Satomi
    Tanimura, Keiko
    Okura, Naoko
    Hirose, Kazuki
    Uda, Sayaka
    Shiotsu, Shinsuke
    Hirai, Soichi
    Hiranuma, Osamu
    Harada, Taishi
    Shimamoto, Takayuki
    Iwasaku, Masahiro
    Kaneko, Yoshiko
    Uchino, Junji
    Takeda, Takayuki
    Takayama, Koichi
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [50] Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors
    Abbar, B.
    Castelbajac, V. De
    Gougis, P.
    Assoun, S.
    Pluvy, J.
    Tesmoingt, C.
    Theou-Anton, N.
    Cazes, A.
    Namour, C.
    Khalil, A.
    Gounant, V.
    Besse, B.
    Zalcman, G.
    Brosseau, S.
    LUNG CANCER, 2021, 152 : 109 - 118